---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000011"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:34:44.967634+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer

## Summary
- GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
- Patients with immune activation signature had median PFS 7.5 months vs 5.6 months for those without.
- AWARE-1 breast cancer study: pelareorep drove tertiary lymphoid structure formation in select patients.
- Pelareorep stimulated RAS-specific T-cell clones in gastrointestinal cancers, presented at a future meeting.

## SEC filing metadata
- accession: 0001129928-26-000011
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000011/0001129928-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000011/oncy-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000011
- JSON: https://secwatch.observer/filing/0001129928-26-000011.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.